[ad_1]
BioNTech announced to the public that the vaccine they developed with Pfizer was called Comirnaty.
The company announced that its goal is to supply 50 million doses of vaccines by the end of 2020 and one billion 300 million doses by the end of 2021. The vaccines will be carried in cold-air boxes that can carry 1,000 to 5,000 doses of vaccine. . In Germany, where the company is located, the distribution of vaccines will be carried out to 450 vaccination centers through 25 distribution centers.
TYPE OF DOCTOR: PREPARED IN 10 MONTHS
BioNTech’s medical research manager and founding partner of the company, Özlem Türeci, shared information about the vaccine preparation process at the press conference. Stating that the vaccine was prepared as a result of a 10-month project called “Speed of Light,” Türeci said that testing of the first phase of the vaccine began on April 23, 2020.
95 PERCENT IMPACT
Türeci said that the vaccine, which began the second phase of trials on July 27, showed an efficiency of 95 percent in the third phase of trials conducted in approximately 44,000 subjects.
The third phase of the trial people who participated in the US, Germany, Turkey, South Africa, more than 40 percent of them from Brazil and Argentina said that when choosing between the ages of 65-85. The vaccine was noted to have side effects such as headache and fatigue, headache in 2 percent, and fatigue in 3.8 percent of the patients who were administered. Other than that, it was stated that the vaccine was generally well tolerated.
The vaccine was indicated to consist of mRNA, sugar, salt, lipids, and water for injection.
DOES THE MUTATION VACCINE REDUCE THE EFFECT?
